CONFIDENTIAL TREATMENT REQUESTED UNDER RULE 24B-2
UNDER THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED.
[*****] INDICATES OMITTED MATERIAL THAT IS THE SUBJECT OF A CONFIDENTIAL TREATMENT REQUEST FILED SEPARATELY WITH THE COMMISSION. THE OMITTED MATERIAL HAS BEEN FILED SEPARATELY WITH THE COMMISSION.
is an industry leader in Alzheimer’s research, with numerous ongoing scientific programs that target suspected causes of
the disease, including amyloid plaques and tau tangles,” said Mark Mintun, M.D., vice president of neurodegeneration and
pain research at Lilly. “This agreement with AC Immune represents another opportunity to hopefully make progress against
this devastating disease, and we look forward to together bringing tau aggregation inhibitors into clinical development.”
will be reflected in Lilly's reported results and financial guidance according to Generally Accepted Accounting Principles (GAAP).
There will be no change to Lilly's 2018 non-GAAP earnings per share guidance as a result of this transaction. This transaction
is subject to clearance under the Hart-Scott-Rodino Antitrust Improvements Act and other customary closing conditions.
AC Immune’s Tau Morphomers™
chemical series of small molecules (MorphomersTM) have been identified which selectively and potently reduce toxic
intracellular misfolded and aggregated tau. Targeting intracellular misfolded and aggregated tau is widely recognized as an important
and attractive potential approach for interfering with the spread of tau pathology throughout the brain. In some proof-of-concept
tauopathy models, reduction of tau pathology was also accompanied by a reduction of associated neuroinflammatory markers –
another key pathologic feature of Alzheimer’s disease (AD).
is a clinical-stage Swiss-based biopharmaceutical company, listed on NASDAQ, which aims to become a global leader in precision
medicine for neurodegenerative diseases. The Company designs, discovers and develops therapeutic as well as diagnostic products
intended to prevent and modify diseases caused by misfolding proteins. AC Immune’s two proprietary technology platforms
create antibodies, small molecules and vaccines designed to address a broad spectrum of neurodegenerative indications, such as
Alzheimer’s disease (AD). The Company’s pipeline features nine therapeutic and three diagnostic product candidates
– with five product candidates currently in clinical trials.
Eli Lilly and Company
a global healthcare leader that unites caring with discovery to create medicines that make life better for people around the world.
We were founded more than a century ago by a man committed to creating high-quality medicines that meet real needs, and today
we remain true to that mission in all our work. Across the globe, Lilly employees work to discover and bring life-changing medicines
to those who need them, improve the understanding and management of disease, and give back to communities through philanthropy
and volunteerism. To learn more about Lilly, please visit us at www.lilly.com and http://newsroom.lilly.com/social-channels.
release contains statements that constitute “forward-looking statements” within the meaning of Section 27A of the
Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. Forward-looking statements are statements other
than historical fact and may include statements that address future operating, financial or business performance or AC Immune’s
strategies or expectations. In some cases, you can identify these statements by forward-looking words such as “may,”
“might,” “will,” “should,” “expects,” “plans,” “anticipates,”
“believes,” “estimates,” “predicts,” “projects,” “potential,” “outlook”
or “continue,” and other comparable terminology. Forward-looking statements are based on management’s current
expectations and beliefs and involve significant risks and uncertainties that could cause actual results, developments and business
decisions to differ materially from those contemplated by these statements. These risks and uncertainties include those described
under the captions “Item 3. Key Information – Risk Factors” and “Item 5. Operating and Financial Review
and Prospects” in AC Immune’s Annual Report on Form 20-F and other filings with the Securities and Exchange Commission.
Forward-looking statements speak only as of the date they are made, and AC Immune does not undertake any obligation to update
them in light of new information, future developments or otherwise, except as may be required under applicable law. All forward-looking
statements are qualified in their entirety by this cautionary statement.